You are here

  • Home
  • Archive
  • Volume 24, Issue 2
  • Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)

Citation Tools

Article menu
Download PDFPDF
Uterine Cancer
Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Emons G, Gorchev G, Harter P, et al
Efficacy and Safety of AEZS-108 (LHRH Agonist Linked to Doxorubicin) in Women With Advanced or Recurrent Endometrial Cancer Expressing LHRH Receptors: A Multicenter Phase 2 Trial (AGO-GYN5)
International Journal of Gynecologic Cancer 2014;24:260-265.